Aprea Therapeutics (NASDAQ:APRE) Trading Down 2.5% – What’s Next?

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s stock price dropped 2.5% on Monday . The stock traded as low as $2.34 and last traded at $2.34. Approximately 10,321 shares were traded during trading, a decline of 45% from the average daily volume of 18,909 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Stock Down 2.5 %

The stock has a market cap of $12.72 million, a price-to-earnings ratio of -0.83 and a beta of 0.82. The firm’s 50 day moving average is $3.30 and its two-hundred day moving average is $3.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC grew its position in Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Aprea Therapeutics in the 4th quarter worth about $43,000. Landscape Capital Management L.L.C. bought a new position in Aprea Therapeutics in the 4th quarter worth about $116,000. Finally, LPL Financial LLC bought a new position in Aprea Therapeutics in the 4th quarter worth about $53,000. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.